nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2011-15-3-18-25nefr-492Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESГОМОЦИСТЕИН: РОЛЬ В РАЗВИТИИ И ПРОГРЕССИРОВАНИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕКHOMOCYSTEINE: ROLE IN THE DEVELOPMENT AND PROGRESSION OF CHRONIC RENAL DISEASEКОНЮХЕ. А.KONYUCHE. A.

Кафедра педиатрии №2

НАУМОВА. В.NAUMOVA. V.ПАРАМОНОВАН. С.PARAMONOVAN. S.

Кафедра педиатрии №2

Гродненский государственный медицинский университетRussian Federationцентральная научно-исследовательская лаборатория Гродненского государственного медицинского университетаRussian Federation2011100320111531825Copyright © КОНЮХ Е.А., НАУМОВ А.В., ПАРАМОНОВА Н.С., 20112011КОНЮХ Е.А., НАУМОВ А.В., ПАРАМОНОВА Н.С.KONYUCH E.A., NAUMOV A.V., PARAMONOVA N.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/492

Гомоцистеин (Hcy) - серосодержащая аминокислота, повышенный уровень (гипергомоцистеинемия, HHcy) которой является предиктором неблагоприятного течения ряда заболеваний. В обзоре литературы рассмотрены биохимические основы влияния HHcy на развитие и прогрессирование хронической болезни почек и осложнения со стороны сердечно-сосудистой системы. Представлены данные о способах коррекции HHcy.

Homocysteine (Hcy) is sulfurcontaining aminoacide and its high level (hyperhomocysteinemia, HHcy) is a predictor of unfavorable event of diseases. Biochemical bases of influence of HHcy to the development and progression of chronic renal disease and cardiovascular complications are discussed in this review. Correction ways of HHcy are presented.

гомоцистеингипергомоцистеинемияхроническая болезнь почеклечениеhomocysteinehyperhomocysteinemiachronic renal diseasetreatmentReferencesVanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascularmorbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascularmorbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056Баранов АА, Сергеева ТВ. Достижения и перспективы развития нефрологии детского возраста. Вопросы современной педиатрии 2007; 6: 20-24Баранов АА, Сергеева ТВ. Достижения и перспективы развития нефрологии детского возраста. Вопросы современной педиатрии 2007; 6: 20-24Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22: 2011-2022Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22: 2011-2022Mackenzie HS, Brenner BM. Current strategies for retarding progression of renal disease. Am J Kidney Dis 1998; 31: 161-170Mackenzie HS, Brenner BM. Current strategies for retarding progression of renal disease. Am J Kidney Dis 1998; 31: 161-170Shishehbor MH, Oliveira LP, Lauer MS, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101: 1741-1746Shishehbor MH, Oliveira LP, Lauer MS, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101: 1741-1746Schroecksnadel K, Frick B, Wirleitner B, et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004; 5(1): 107-118Schroecksnadel K, Frick B, Wirleitner B, et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004; 5(1): 107-118Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors 2010; 36(1): 19-24Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors 2010; 36(1): 19-24Наумов АВ. Роль нарушений процессов метилирования и обмена метионина в патогенезе заболеваний человека. Журн Гроднен гос мед ун-та 2007; 1: 4-7Наумов АВ. Роль нарушений процессов метилирования и обмена метионина в патогенезе заболеваний человека. Журн Гроднен гос мед ун-та 2007; 1: 4-7Naumov AV, Pakulnevich YF, Doroshenko EM et al. Hyperhomocysteinaemia at various forms of pancreatitis. Acta Biochimica Polonica 2008; 55(3): 191Naumov AV, Pakulnevich YF, Doroshenko EM et al. Hyperhomocysteinaemia at various forms of pancreatitis. Acta Biochimica Polonica 2008; 55(3): 191Naunrov AV, Matveenko PA, Doroshenko EM et al. The level of total plasma homocysteine in adolescents from rural area of Belarus and its correction. Acta Biochimica Polonica 2009; 56(1.3): 198Naunrov AV, Matveenko PA, Doroshenko EM et al. The level of total plasma homocysteine in adolescents from rural area of Belarus and its correction. Acta Biochimica Polonica 2009; 56(1.3): 198Minniti G, Cerone R, Piana A, et al. Plasma and serum total homocysteine concentrations in pediatric patients, evaluated by high-performance liquid chromatography with fluorescence. Clin Chem Lab Med 2000; 38: 675-676Minniti G, Cerone R, Piana A, et al. Plasma and serum total homocysteine concentrations in pediatric patients, evaluated by high-performance liquid chromatography with fluorescence. Clin Chem Lab Med 2000; 38: 675-676Ueland PM, Bjorke Monsen A-L. Total homocysteine is making its way into pediatric laboratory diagnostics. Eur J Clin Invest 2001; 31(11): 928-930Ueland PM, Bjorke Monsen A-L. Total homocysteine is making its way into pediatric laboratory diagnostics. Eur J Clin Invest 2001; 31(11): 928-930Aguilar B, Rojas JC, Collados MT. Metabolism of homocysteine and its relationship with cardiovascular disease. J Thromb Thrombolysis 2004; 18(2): 75-87Aguilar B, Rojas JC, Collados MT. Metabolism of homocysteine and its relationship with cardiovascular disease. J Thromb Thrombolysis 2004; 18(2): 75-87Robinson K. Data presented at: 69th Scientific Sessions of the American Heart Assosiation; November 12, 1996; New Orleans, LaRobinson K. Data presented at: 69th Scientific Sessions of the American Heart Assosiation; November 12, 1996; New Orleans, LaПлоцкий АР, Егорова ТЮ, Наумов АВ. Возможности прогнозирования и диагностики врождённых пороков развития плода на основе определения уровня гомоцистеина в плазме крови беременных женщин. Журн Гроднен гос мед ун-та 2009; 1: 56-59Плоцкий АР, Егорова ТЮ, Наумов АВ. Возможности прогнозирования и диагностики врождённых пороков развития плода на основе определения уровня гомоцистеина в плазме крови беременных женщин. Журн Гроднен гос мед ун-та 2009; 1: 56-59Плоцкий АР, Егорова ТЮ, Наумов АВ, и др. Коррекция уровня гомоцистеина в плазме крови женщин. Рецепт 2008; 59(3): 45-50Плоцкий АР, Егорова ТЮ, Наумов АВ, и др. Коррекция уровня гомоцистеина в плазме крови женщин. Рецепт 2008; 59(3): 45-50Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995;41(3): 340-342Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995;41(3): 340-342Mudd SH, Finkelstein JD, Refsum H et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000; 20(7): 1704-1706Mudd SH, Finkelstein JD, Refsum H et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000; 20(7): 1704-1706Glowacki R, Jakubowski H. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 2004; 279(12): 10864-10871Glowacki R, Jakubowski H. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 2004; 279(12): 10864-10871Friedman AN, Bostom AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181-2189Friedman AN, Bostom AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181-2189Hultberg B, Andersson A, Isaksson A. Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture line (human histiocytic cell line U-937). Biochim Biophys Acta 1995; 1269(1): 6-12Hultberg B, Andersson A, Isaksson A. Metabolism of homocysteine, its relation to the other cellular thiols and its mechanism of cell damage in a cell culture line (human histiocytic cell line U-937). Biochim Biophys Acta 1995; 1269(1): 6-12Bjorke-Monsen AL, Ueland PM, Vollset SE et al. Determinants of cobalamin status in newborns. Pediatrics 2001; 108: 624-630Bjorke-Monsen AL, Ueland PM, Vollset SE et al. Determinants of cobalamin status in newborns. Pediatrics 2001; 108: 624-630Delvin EE, Rozen R, Merouani A et al. Influence of methylenetetrahydrofolate reductase genotype, age, vitamine B12 and folate status on plasma homocysteine in children. Am J Clin Nutr 2000; 72: 1469-1473Delvin EE, Rozen R, Merouani A et al. Influence of methylenetetrahydrofolate reductase genotype, age, vitamine B12 and folate status on plasma homocysteine in children. Am J Clin Nutr 2000; 72: 1469-1473Prathapasinghe GA, Siow YL, Xu Z. Inhibition of cystathionine-beta-synthase activity during renal ischemia-reperfusion: role of pH and nitric oxide. Am J Physiol Renal Physiol 2008; 295(4): F912-922Prathapasinghe GA, Siow YL, Xu Z. Inhibition of cystathionine-beta-synthase activity during renal ischemia-reperfusion: role of pH and nitric oxide. Am J Physiol Renal Physiol 2008; 295(4): F912-922Woo CW, Siow YL, Pierce GN et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. Am J Physiol Endocrinol Metab 2005; 288(5): E1002-1010Woo CW, Siow YL, Pierce GN et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. Am J Physiol Endocrinol Metab 2005; 288(5): E1002-1010Clarke R, Refsum H, Birks J, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr 2003; 77(5): 1241-1247Clarke R, Refsum H, Birks J, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr 2003; 77(5): 1241-1247Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr 2002; 75(4): 616-658Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr 2002; 75(4): 616-658Obeid R, Herrmann W. Homocysteine and lipids: Sadenosyl methionine as a key intermediate. FEBS Lett 2009; 583(8): 1215-1225Obeid R, Herrmann W. Homocysteine and lipids: Sadenosyl methionine as a key intermediate. FEBS Lett 2009; 583(8): 1215-1225Swanson DA, Liu ML, Baker PJ et al. Targeted disruption of the methionine synthase gene in mice. Mol Cell Biol 2001; 21(4): 1058-1065Swanson DA, Liu ML, Baker PJ et al. Targeted disruption of the methionine synthase gene in mice. Mol Cell Biol 2001; 21(4): 1058-1065Brustolin S, Giugliani R, Felix TM. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010; 43: 1-5Brustolin S, Giugliani R, Felix TM. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010; 43: 1-5Francis ME, Eggers PW, Hostetter TH, et al. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004; 66(1): 303-312Francis ME, Eggers PW, Hostetter TH, et al. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004; 66(1): 303-312Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1(5): 228-237Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1(5): 228-237Hoekstra M, Haagsma CJ, Doelman CJ, et al. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 2005; 64(1): 141-143Hoekstra M, Haagsma CJ, Doelman CJ, et al. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 2005; 64(1): 141-143Lawrence de Koning AB, Werstuck GH, Zhou J, et al. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003; 36(6): 431-441Lawrence de Koning AB, Werstuck GH, Zhou J, et al. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003; 36(6): 431-441McCully KS. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci 2009; 39(3): 219-232McCully KS. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci 2009; 39(3): 219-232Massy ZA, Ceballos I, Chadefaux-Vekemens B, еt al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int Suppl 2001; 78: S243-S245Massy ZA, Ceballos I, Chadefaux-Vekemens B, еt al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int Suppl 2001; 78: S243-S245Goligorsky MS. Frontiers in Nephrology: Viewing the Kidney through the Heart-Endothelial Dysfunction in Chronic Kidney Disease. J Am Soc Nephrol 2007; 18: 2833-2835Goligorsky MS. Frontiers in Nephrology: Viewing the Kidney through the Heart-Endothelial Dysfunction in Chronic Kidney Disease. J Am Soc Nephrol 2007; 18: 2833-2835Bostom A, Brosnan JT, Hall B et al. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116(1): 59-62Bostom A, Brosnan JT, Hall B et al. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116(1): 59-62Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 2004; 44(3): 437-445Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 2004; 44(3): 437-445Taha S, Azzi A, Ozer NK. Homocysteine induces DNA synthesis and proliferation of vascular smooth muscle cells by a hydrogen peroxide-independent mechanism. Antioxid Redox Signal 199l; 1(3): 365-369Taha S, Azzi A, Ozer NK. Homocysteine induces DNA synthesis and proliferation of vascular smooth muscle cells by a hydrogen peroxide-independent mechanism. Antioxid Redox Signal 199l; 1(3): 365-369Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97(1): 146-153Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97(1): 146-153Majors AK, Sengupta S, Jacobsen DW, et al. Upregulation of smooth muscle cell collagen production by homocysteine-insight into the pathogenesis of homocystinuria. Mol Genet Metab 2002; 76(2): 92-99Majors AK, Sengupta S, Jacobsen DW, et al. Upregulation of smooth muscle cell collagen production by homocysteine-insight into the pathogenesis of homocystinuria. Mol Genet Metab 2002; 76(2): 92-99Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci 2003; 325(4): 209-213Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci 2003; 325(4): 209-213Sierakowska-Fijaiek A, Baj Z, Kaczmarek P, et al. Estimation of relation between homocysteine concentration and selected lipid parameters and adhesion molecules concentration in children with atherosclerosis risk factors. Pol Merkur Lekarski 2008; 25(148): 356-360Sierakowska-Fijaiek A, Baj Z, Kaczmarek P, et al. Estimation of relation between homocysteine concentration and selected lipid parameters and adhesion molecules concentration in children with atherosclerosis risk factors. Pol Merkur Lekarski 2008; 25(148): 356-360Liang JQ, Wu YL, Xu HB et al. The endothelium injuries caused by homocysteine and treatmental effects of Tongxinluo powder. Zhongguo Ying Yong Sheng LiXue Za Zhi 2008; 24(1): 66-70Liang JQ, Wu YL, Xu HB et al. The endothelium injuries caused by homocysteine and treatmental effects of Tongxinluo powder. Zhongguo Ying Yong Sheng LiXue Za Zhi 2008; 24(1): 66-70Weiss N, Keller C, Hoffmann U, et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002; 7(3): 227-239Weiss N, Keller C, Hoffmann U, et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002; 7(3): 227-239Outinen PA, Sood SK, Pfeifer SI, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999; 94(3): 959-967Outinen PA, Sood SK, Pfeifer SI, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999; 94(3): 959-967Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 1999; 9(1-2): 49-54Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 1999; 9(1-2): 49-54Tyagi SC, Smiley LM, Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 1999; 77(12): 950-957Tyagi SC, Smiley LM, Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 1999; 77(12): 950-957Upchurch GR, Welch GN, Fabian AJ, et al. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 1997; 132: 177-185Upchurch GR, Welch GN, Fabian AJ, et al. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 1997; 132: 177-185Tyagi N, Gillespie W, Vacek JC, et al. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol 2009; 220: 57-266Tyagi N, Gillespie W, Vacek JC, et al. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol 2009; 220: 57-266Tawakol A, Omland T, Gerhard M, еt al. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121Tawakol A, Omland T, Gerhard M, еt al. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121Buccianti G, Raselli S, Baragetti I, et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17(5): 857-864Buccianti G, Raselli S, Baragetti I, et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002; 17(5): 857-864Upchurch GR, Welch GN, Randev N, et al. The effect of homocysteine on endothelial nitric oxide production. FASEB J 1995; 9: A876. AbstractUpchurch GR, Welch GN, Randev N, et al. The effect of homocysteine on endothelial nitric oxide production. FASEB J 1995; 9: A876. AbstractHuang RF, Hsu YC, Lin HL, et al. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 2001; 131(1): 33-38Huang RF, Hsu YC, Lin HL, et al. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 2001; 131(1): 33-38Cattell V. Nitric oxide and glomerulonephritis. Kidney Int 2002; 61(3): 816-821Cattell V. Nitric oxide and glomerulonephritis. Kidney Int 2002; 61(3): 816-821Ishizuka S, Cunard R, Poucell-Hatton S, et al. Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis. J Am Soc Nephrol 2000; 11(12): 2256-2264Ishizuka S, Cunard R, Poucell-Hatton S, et al. Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis. J Am Soc Nephrol 2000; 11(12): 2256-2264Stoessel A, Paliege A, Theilig F, et al. Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition. Am J Physiol Renal Physiol 2008; 295(3): F717-725Stoessel A, Paliege A, Theilig F, et al. Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition. Am J Physiol Renal Physiol 2008; 295(3): F717-725O'Riordan E, Mendelev N, Patschan S, et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol 2007; 292(1): H285-294O'Riordan E, Mendelev N, Patschan S, et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol 2007; 292(1): H285-294Addabbo F, Ratliff B, Park HC, et al. The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. Am J Pathol 2009; 174(1): 34-43Addabbo F, Ratliff B, Park HC, et al. The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. Am J Pathol 2009; 174(1): 34-43Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30(9):1142-1150Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30(9):1142-1150Stoehlinger MC, Tsao PS, Her JH, Kimoto M et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104(21): 2569-2575Stoehlinger MC, Tsao PS, Her JH, Kimoto M et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104(21): 2569-2575Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl 2003; 4(4): 61-65Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl 2003; 4(4): 61-65Qureshi I, Chen H, Brown AT, et al. Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor. Vasc Med 2005; 10(3): 215-223Qureshi I, Chen H, Brown AT, et al. Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor. Vasc Med 2005; 10(3): 215-223Onozato ML, Tojo A, Leiper J, et al. Expression of NG, NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008; 57(1): 172-180Onozato ML, Tojo A, Leiper J, et al. Expression of NG, NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008; 57(1): 172-180Dayal S, Rodionov RN, Arning E, et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008; 295(2): H816-H825Dayal S, Rodionov RN, Arning E, et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008; 295(2): H816-H825Ueda S, Yamagishi S, Matsumoto Y, et al. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007; 11(2): 115-121Ueda S, Yamagishi S, Matsumoto Y, et al. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007; 11(2): 115-121Nangaku M, Nishi H, Miyata T. Role of chronic hypoxia and hypoxia inducible factor in kidney disease. Chin Med J (Engl) 2008; 121(3): 257-264Nangaku M, Nishi H, Miyata T. Role of chronic hypoxia and hypoxia inducible factor in kidney disease. Chin Med J (Engl) 2008; 121(3): 257-264Fu YF, Xiong Y, Guo Z. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol 2005; 508(1-3): 167-175Fu YF, Xiong Y, Guo Z. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol 2005; 508(1-3): 167-175Notsu Y, Nabika T, Bokura H, et al. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens 2009; 22(3): 257-262Notsu Y, Nabika T, Bokura H, et al. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens 2009; 22(3): 257-262Pexa A, Boeger RH, Henle T, et al. Effects of moderate hyperhomocysteinaemia induced by 4 weeks methionine-enriched diet on metabolite profile and mesenteric artery function in rats. Br J Nutr 2008; 99(5): 993-999Pexa A, Boeger RH, Henle T, et al. Effects of moderate hyperhomocysteinaemia induced by 4 weeks methionine-enriched diet on metabolite profile and mesenteric artery function in rats. Br J Nutr 2008; 99(5): 993-999Подчерняева НС, Вашакмадзе НС, Меграбян МФ. Факторы риска развития тромботических осложнений при системной красной волчанке и дерматомиозите у детей. Российский педиатрический журнал 2006; 5: 30-34Подчерняева НС, Вашакмадзе НС, Меграбян МФ. Факторы риска развития тромботических осложнений при системной красной волчанке и дерматомиозите у детей. Российский педиатрический журнал 2006; 5: 30-34Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 2000; 96(3): 966-972Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 2000; 96(3): 966-972Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77(6): 1909-1916Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77(6): 1909-1916Stein J, Mc Bride PE. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998; 158(12): 1301-1306Stein J, Mc Bride PE. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998; 158(12): 1301-1306Lentz SR, Salder JE Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914Lentz SR, Salder JE Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914Himmelfarb J, Stanvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538Himmelfarb J, Stanvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538Terawaki H, Yoshimura K, Hasegawa T, et al. Oxidative stress in enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004; 66: 1988-1993Terawaki H, Yoshimura K, Hasegawa T, et al. Oxidative stress in enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004; 66: 1988-1993Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99Tyagi N, Ovechkin AV, Lominadze D, et al. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 2006; 98(5): 1150-1162Tyagi N, Ovechkin AV, Lominadze D, et al. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 2006; 98(5): 1150-1162Au-Yeung KK, Woo CW, Sung FL, et al. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004; 94(1): 2836Au-Yeung KK, Woo CW, Sung FL, et al. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004; 94(1): 2836Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004; 35(2): 345-347Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004; 35(2): 345-347Garaliene V. The main determinants of endothelial dysfunction. Medicina (Kaunas) 2006; 42(5): 362-369Garaliene V. The main determinants of endothelial dysfunction. Medicina (Kaunas) 2006; 42(5): 362-369Fischer PA, Dominguez GN, Cuniberti LA, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved? J Am Soc Nephrol 2003; 14(3): 653-660Fischer PA, Dominguez GN, Cuniberti LA, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved? J Am Soc Nephrol 2003; 14(3): 653-660Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106(4): 483-491Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106(4): 483-491Weiss N, Keller C, Hoffmann U, et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002; 7(3): 227-239Weiss N, Keller C, Hoffmann U, et al. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002; 7(3): 227-239Lang D, Kredan MB, Moat SJ, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol 2000; 20(2): 422-427Lang D, Kredan MB, Moat SJ, et al. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler Thromb Vasc Biol 2000; 20(2): 422-427Ricci C, Pastukh V, Leonard J, et al. Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis. Am J Physiol Cell Physiol 2008; 294(2): C413-422Ricci C, Pastukh V, Leonard J, et al. Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis. Am J Physiol Cell Physiol 2008; 294(2): C413-422Vartanian V, Lowell B, Minko IG, et al. The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci USA 2006; 103(6): 1864-1869Vartanian V, Lowell B, Minko IG, et al. The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. Proc Natl Acad Sci USA 2006; 103(6): 1864-1869Zhang D, Mott JL, Farrar P, et al. Mitochondrial DNA mutations activate the mitochondrial apoptotic pathway and cause dilated cardiomyopathy. Cardiovasc Res 2003; 57(1): 147-157Zhang D, Mott JL, Farrar P, et al. Mitochondrial DNA mutations activate the mitochondrial apoptotic pathway and cause dilated cardiomyopathy. Cardiovasc Res 2003; 57(1): 147-157Lewis W, Day BJ, Kohler JJ, et al. Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. Lab Invest 2007; 87(4): 326-335Lewis W, Day BJ, Kohler JJ, et al. Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. Lab Invest 2007; 87(4): 326-335Hegde ML, Hazra TK, Mitra S. Functions of disordered regions in mammalian early base excision repair proteins. Cell Mol Life Sci 2010; 67(21): 3573-3587Hegde ML, Hazra TK, Mitra S. Functions of disordered regions in mammalian early base excision repair proteins. Cell Mol Life Sci 2010; 67(21): 3573-3587Duthie SJ, Grant G, Pirie LP, et al. Folate deficiency alters hepatic and colon MGMT and OGG-1 DNA repair protein expression in rats but has no effect on genome-wide DNA methylation. Cancer Prev Res (Phila) 2010; 3(1): 92-100Duthie SJ, Grant G, Pirie LP, et al. Folate deficiency alters hepatic and colon MGMT and OGG-1 DNA repair protein expression in rats but has no effect on genome-wide DNA methylation. Cancer Prev Res (Phila) 2010; 3(1): 92-100Bostom AG, Kronenberg F, Jacques PF, et al. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. Atherosclerosis 2001; 159(1): 219-223Bostom AG, Kronenberg F, Jacques PF, et al. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. Atherosclerosis 2001; 159(1): 219-223Смирнов АВ, Добронравов ВА, Голубев РВ и др. Распространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек Нефрология 2005; 9(2): 48-52Смирнов АВ, Добронравов ВА, Голубев РВ и др. Распространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек Нефрология 2005; 9(2): 48-52Perna AF, Ingrosso D, Lombardi C, et al. Homocysteine in uremia. Am J Kidney Dis 2003; 41(3, S1.): 123-126Perna AF, Ingrosso D, Lombardi C, et al. Homocysteine in uremia. Am J Kidney Dis 2003; 41(3, S1.): 123-126Kumagai H, Katoh S. Hirosawa K. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62: 1219-1228Kumagai H, Katoh S. Hirosawa K. Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002; 62: 1219-1228Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40(4): 230-235Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40(4): 230-235Fowler B. The folat cycle and disease in humans. Kidney Int 2001; 59(S 78): 221-229Fowler B. The folat cycle and disease in humans. Kidney Int 2001; 59(S 78): 221-229van Guldener C, Donker AJM, Jacobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54(1): 166-169van Guldener C, Donker AJM, Jacobs C et al. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54(1): 166-169Hustad S, Ueland PM, Vollset SE, et al. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46(8 Pt1): 1065-1071Hustad S, Ueland PM, Vollset SE, et al. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46(8 Pt1): 1065-1071Schroecksnadel K, Frick B, Wirleitner B, et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004; 5(1): 107-118Schroecksnadel K, Frick B, Wirleitner B, et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004; 5(1): 107-118Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101(7): 2483-2488Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101(7): 2483-2488Craig SA. Betaine in human nutrition. Am J Clin Nutr 2004; 80(3): 539-549Craig SA. Betaine in human nutrition. Am J Clin Nutr 2004; 80(3): 539-549Schwab U, Turrunen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76(5): 961-967Schwab U, Turrunen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76(5): 961-967Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr 2003; 133(5): 1291-1295Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr 2003; 133(5): 1291-1295Olthof MR, van Vliet T, Boelsma E, et al. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr 2003; 133(12): 4135-4138Olthof MR, van Vliet T, Boelsma E, et al. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr 2003; 133(12): 4135-4138Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet 2002; 108(1): 57-63Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet 2002; 108(1): 57-63Collinsova M, Strakova J, Jiracek J, et al. Inhibition of betaine-homocysteine S-methyltransferase causes hyperhomocysteinemia in mice. J Nutr 2006; 136(6): 1493-1497Collinsova M, Strakova J, Jiracek J, et al. Inhibition of betaine-homocysteine S-methyltransferase causes hyperhomocysteinemia in mice. J Nutr 2006; 136(6): 1493-1497Strakova J, Williams KT, Gupta S, et al. Dietary intake of S-(alpha-carboxybutyl)-DL-homocysteine induces hyperhomocysteinemia in rats. Nutr Res 2010; 30(7): 492-500Strakova J, Williams KT, Gupta S, et al. Dietary intake of S-(alpha-carboxybutyl)-DL-homocysteine induces hyperhomocysteinemia in rats. Nutr Res 2010; 30(7): 492-500Poge U, Look M, Gerhardt T, et al. Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis. A pilot study. Renal Failure 2004; 26(6): 703-708Poge U, Look M, Gerhardt T, et al. Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis. A pilot study. Renal Failure 2004; 26(6): 703-708Brattstrum L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126(4 Suppl): 1276S-1280SBrattstrum L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126(4 Suppl): 1276S-1280SCattaneo M. Hyperhomocysteinemia: an important risk factor for cardiovascular disease? Potentially,yes. J Thromb Haemost 2003; 1: 1878-1879Cattaneo M. Hyperhomocysteinemia: an important risk factor for cardiovascular disease? Potentially,yes. J Thromb Haemost 2003; 1: 1878-1879Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102(20): 2479-2483Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102(20): 2479-2483Stam F, van Guldener C. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 2005; 67(1): 259-264Stam F, van Guldener C. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 2005; 67(1): 259-264McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007; 86: 1563S-1568SMcCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007; 86: 1563S-1568SSamman S, Sivarajah G, Man JC, et al. A mixed fruit and vegetable concentrate increases plasma antioxidant vitamins and folate and lowers plasma homocysteine in men. J Nutr 2003; 133(7): 2188-2193Samman S, Sivarajah G, Man JC, et al. A mixed fruit and vegetable concentrate increases plasma antioxidant vitamins and folate and lowers plasma homocysteine in men. J Nutr 2003; 133(7): 2188-2193Stroes ESG, van Faassen EE, Martasek P, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86(11): 1129-1134Stroes ESG, van Faassen EE, Martasek P, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86(11): 1129-1134Sakabe K, Fukuda N, Wakayama K, et al. Lipidaltering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 497-500Sakabe K, Fukuda N, Wakayama K, et al. Lipidaltering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 497-500Zhang B, Noda K, Matsunaga A, et al. A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia. J Atheroscler Thromb 2005; 12: 41-47Zhang B, Noda K, Matsunaga A, et al. A comparative crossover study of the effects of fluvastatin and pravastatin (FP-COS) on circulating autoantibodies to oxidized LDL in patients with hypercholesterolemia. J Atheroscler Thromb 2005; 12: 41-47Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248Nanayakkara WB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease results from the anti-oxidant therapy in chronic renal insufficiency (ATIC) study. Arch Intern Med 2007; 167: 1262-1270Nanayakkara WB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease results from the anti-oxidant therapy in chronic renal insufficiency (ATIC) study. Arch Intern Med 2007; 167: 1262-1270

The authors declare that there are no conflicts of interest present.